



ASX & Media Release

Market Update

Melbourne, Australia; 29 March, 2019: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company is pleased to update the market on the progress of a range of activities being pursued by the Company.

PAT-DX1 process development

As announced in October 2018, the Company has engaged an international service provider for cell line development of PAT-DX1. This program is fundamental to the advancement of PAT-DX1 towards the clinic as a stable cell line is a critical component of the development pathway for therapeutic antibodies. Patrys is very pleased with the progress made to date on this program, and will update the market when appropriate milestones are achieved.

Pre-clinical development of PAT-DX1

The Company has previously indicated that it anticipated announcing data from two pre-clinical studies in Q1, 2019 (PAT-DX1 plus radiation in a mouse model of triple negative breast cancer brain metastases, and PAT-DX1 plus radiation in a mouse model of glioblastoma). The first of these experiments is ongoing, and the second experiment can only commence after the first experiment is complete. Accordingly, we now expect to report the data from both studies in Q2, 2019. At this stage the Company still believes that it will be able to report on its third study (PAT-DX1 plus temozolamide in a mouse model of glioblastoma) before the end of H1, 2019.

First patent granted for Deoxymab 5C6

The Company has received a Notice of Grant from the United States Patent Office for the 5C6 antibody that Patrys has licenced from Yale University. The patent, "*Cell Penetrating Nucleolytic Antibody Based Cancer Therapy*" (Patent number 10,238,742) was granted on March 26, 2019 in the US. The patent is directed towards pharmaceutical compositions inhibiting proliferation of cancer cells deficient in DNA damage repair. Whilst 5C6 is not currently a development priority for Patrys, this new patent further strengthens the Company's position in the field of cell penetrating antibodies for the treatment of cancer.

Additional non-dilutive capital

Pleasingly, over the past several weeks the Patrys group has received several grants from Australian government departments and agencies worth approximately \$35,000. Some of these funds are to be applied specifically to a program around PAT-DX1 formulation, and the residual funds will be applied to Patrys' ongoing business development efforts.

"Patrys continues to progress its programs in a measured and cost-effective manner," said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. "We believe that the ongoing clinical development program, supported by a strong pipeline of pre-clinical research and an



increasing number of granted patents positions the Company well to build on its strong position in the field of DNA damage repair (DDR) therapeutics.”

-Ends-

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media and IR:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@we-buchan.com

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.